Becton Dickinson May Collaborate with Accelr8 on Rapid Dx Platform | GenomeWeb
NEW YORK (GenomeWeb News) – Becton Dickinson has bought the rights to negotiate with Accelr8 Technology to develop its BACcel rapid diagnostic platform, Accelr8 said Thursday.
 
BD will pay Accelr8 $100,000 for the right to an exclusive negotiation period lasting through March 31, 2008, during which the companies will consider a development and commercialization program for the system. Such an agreement could include licensing rights, an equity investment, a joint development, or other type of development program, said Accelr8.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: genes involved in histone deacetylation in Arabidopsis, effects of pathogenic presenilin-1 mutations, and more.

After a study finds DNA from antibiotic-resistant bacteria in Beijing smog, residents there worry, according to the New York Times.

Canada begins its search for a chief government science advisor, Nature News reports.

A company is using facial recognition tools to identify genetic disorders from pictures, Technology Review reports.